Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Adial Pharmaceuticals, Inc. (ADIL) stock profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Key facts

SymbolADIL
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOCary John Claiborne
Employees5
HeadquartersGlen Allen, VA, US
IPO2018-07-27
Websitewww.adial.com

Explore ADIL on Vantafin

  • Adial Pharmaceuticals, Inc. Overview
  • Adial Pharmaceuticals, Inc. Financials
  • Adial Pharmaceuticals, Inc. News
  • Adial Pharmaceuticals, Inc. Events
  • Adial Pharmaceuticals, Inc. SEC filings
  • Adial Pharmaceuticals, Inc. Insider transactions

Frequently asked questions

What does Adial Pharmaceuticals, Inc. (ADIL) do?
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Where is ADIL stock listed?
Adial Pharmaceuticals, Inc. trades under the ticker ADIL on NASDAQ.
How can I research ADIL's financials and filings?
Vantafin provides Adial Pharmaceuticals, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ADIL profile.